Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The study investigators hypothesize that the pneumonia arising in patients with COVID-19 is largely of immunopathological origin. The investigators will therefore seek to define the immune activation phenotype of patients in respiratory distress and to see if this immune signature is predictive of mortality. Finally, the investigators will look for overproduced inflammatory mediators to identify potential therapeutic targets.
Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of Human Leukocyte Antigen -DR isotype compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of Programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry
Measure: Membrane expression of cluster of differentiation 45RA compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of cluster of differentiation 27 (naïve/central memory/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of CD57 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of cluster of differentiation 27 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of cluster of differentiation 28 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of Human Leukocyte Antigen -DR isotype on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of cluster of differentiation 69 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of cluster of differentiation 56 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of cluster of differentiation 57 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of cluster of differentiation 14 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Membrane expression of cluster of differentiation 16 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Number of regulatory T cells (CD4+CD25hiCD127loFoxP3+). Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Percentage of regulatory T cells (CD4+CD25hiCD127loFoxP3+). Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Immunoglobulin A compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Immunoglobulin G compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Immunoglobulin M compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Ultrasensitive C-Reactive Protein compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Soluble tumor necrosis factor alpha receptor type I compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating E-selectin (cluster of differentiation 62E) compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry
Measure: Rate of circulating Granulocyte Macrophage Colony-Stimulating Factor compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating InterCellular Adhesion Molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interferon beta compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry
Measure: Rate of circulating Interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Interleukin-17A compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Induced Protein 10 (C-X-C motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Monocyte Chemoattractant Protein-1 (C-C Motif Chemokine Ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Macrophage inflammatory protein-1 alpha (C-C Motif Chemokine Ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating Macrophage inflammatory protein-1 beta (C-C Motif Chemokine Ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of circulating P-selectin compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of soluble form of endothelial protein C receptor compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Quantified by flow cytometry; % variation / normal values
Measure: Rate of D-Dimers compared to normal values (based on 150 healthy volunteers previously sampled) Time: Day 0Description: Difference in expression of the biomarkers assayed for primary outcome
Measure: Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 before any respiratory distress against that of 150 volunteers from the general population (data already existing). Time: Day 0Description: Difference in expression of the biomarkers assayed for primary outcome
Measure: Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 with respiratory failure against versus those without respiratory failure Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of E-selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Granulocyte Macrophage Colony-Stimulating Factor levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of InterCellular Adhesion Molecule levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interferon alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interferon gamma levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interleukin-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interleukin-1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interleukin-4 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interleukin-6 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interleukin-8 (C-X-C motif ligand 8) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interleukin-10 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interleukin-12p70 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interleukin-13 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Interleukin-17A levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Induced Protein -10 (C-X-C motif chemokine 10) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Monocyte Chemoattractant Protein-1 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Macrophage Inflammatory Protein-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Macrophage Inflammatory Protein -1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of P-Selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: quantified by Luminex (TruCulture tube system (Myriad RBM))
Measure: Comparison of Tumor necrosis factor alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects Time: Day 0Description: Difference in expression of the 20 inflammatory markers described in outcomes 51-70
Measure: Identify inflammatory mediators over-produced by the PBMC of patients with COVID-19 before respiratory distress Time: Day 0Description: Difference in expression of the 20 inflammatory markers described in outcomes 51-70
Measure: Compare the inflammatory mediators over-produced by the peripheral blood mononuclear cells of patients with COVID-19 with versus without respiratory failure Time: Day 0Description: Performed at the Institut de Génétique Humaine (Montpellier)
Measure: Comparison of transcriptome from peripheral blood mononuclear cells from 12 patients with respiratory failure (from intensive care ward) and 10 without (normal hospitalization) Time: Day 0Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports